DCF — INNOVIS HEALTH
Enterprise Value: $-494.8M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-494.8M
Enterprise Value
$-164.8M
PV of Cash Flows
$-330.0M
PV of Terminal Value
$-531.5M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $554.0M | $-26.3M | -5.0% | $-49.8M | $-45.3M |
| Year 2 | $570.7M | $-21.4M | -4.0% | $-45.6M | $-37.7M |
| Year 3 | $587.8M | $-16.2M | -3.0% | $-41.1M | $-30.9M |
| Year 4 | $605.4M | $-13.6M | -2.0% | $-39.3M | $-26.8M |
| Year 5 | $623.6M | $-12.5M | -2.0% | $-38.9M | $-24.1M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-494.8M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$537.9M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base-0.052538359745916585
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5